Nanosonics Limited

CHIA:NAN Stock Report

Market Cap: AU$976.8m

Nanosonics Valuation

Is NAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NAN (A$3.24) is trading below our estimate of fair value (A$5.04)

Significantly Below Fair Value: NAN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NAN?

Key metric: As NAN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NAN. This is calculated by dividing NAN's market cap by their current earnings.
What is NAN's PE Ratio?
PE Ratio75.3x
EarningsAU$12.97m
Market CapAU$976.84m

Price to Earnings Ratio vs Peers

How does NAN's PE Ratio compare to its peers?

The above table shows the PE ratio for NAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45x
ANN Ansell
40.2x22.8%AU$4.7b
SDI SDI
12x17.8%AU$125.4m
PGC Paragon Care
98.8x37.0%AU$827.7m
ACL Australian Clinical Labs
29.1x16.0%AU$697.5m
NAN Nanosonics
75.3x24.0%AU$976.8m

Price-To-Earnings vs Peers: NAN is expensive based on its Price-To-Earnings Ratio (75.3x) compared to the peer average (41.1x).

Price to Earnings Ratio vs Industry

How does NAN's PE Ratio compare vs other companies in the Global Medical Equipment Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NAN 75.3xIndustry Avg. 28.2xNo. of Companies49PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NAN is expensive based on its Price-To-Earnings Ratio (75.3x) compared to the Global Medical Equipment industry average (27.6x).

Price to Earnings Ratio vs Fair Ratio

What is NAN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NAN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio75.3x
Fair PE Ratio39.5x

Price-To-Earnings vs Fair Ratio: NAN is expensive based on its Price-To-Earnings Ratio (75.3x) compared to the estimated Fair Price-To-Earnings Ratio (39.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NAN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$3.24
AU$3.46
+6.9%
11.2%AU$4.00AU$2.75n/a10
Nov ’25AU$3.21
AU$3.53
+9.9%
12.1%AU$4.20AU$2.75n/a11
Oct ’25AU$3.69
AU$3.53
-4.2%
12.1%AU$4.20AU$2.75n/a11
Sep ’25AU$3.22
AU$3.48
+8.2%
12.5%AU$4.20AU$2.75n/a12
Aug ’25AU$3.21
AU$3.33
+3.8%
16.8%AU$4.20AU$2.55n/a12
Jul ’25AU$2.86
AU$3.20
+12.0%
16.4%AU$4.20AU$2.55n/a12
Jun ’25AU$2.80
AU$3.20
+14.4%
16.4%AU$4.20AU$2.55n/a12
May ’25AU$2.84
AU$3.20
+12.8%
16.4%AU$4.20AU$2.55n/a12
Apr ’25AU$2.74
AU$3.20
+16.9%
16.4%AU$4.20AU$2.55n/a12
Mar ’25AU$2.76
AU$3.20
+16.3%
16.4%AU$4.20AU$2.55n/a12
Feb ’25AU$2.89
AU$3.75
+29.8%
15.6%AU$5.00AU$2.83n/a11
Jan ’25AU$4.39
AU$4.56
+3.9%
14.7%AU$5.46AU$3.65n/a12
Dec ’24AU$4.11
AU$4.65
+13.2%
17.9%AU$6.50AU$3.65n/a12
Nov ’24AU$3.85
AU$4.65
+20.9%
17.9%AU$6.50AU$3.65AU$3.2112
Oct ’24AU$4.19
AU$4.69
+12.0%
17.1%AU$6.50AU$3.75AU$3.6912
Sep ’24AU$4.16
AU$4.59
+10.3%
18.6%AU$6.50AU$3.34AU$3.2213
Aug ’24AU$4.79
AU$4.76
-0.5%
17.9%AU$6.50AU$3.34AU$3.2113
Jul ’24AU$4.73
AU$4.72
-0.1%
19.1%AU$6.50AU$3.34AU$2.8612
Jun ’24AU$5.16
AU$4.72
-8.5%
19.1%AU$6.50AU$3.34AU$2.8012
May ’24AU$5.57
AU$4.71
-15.4%
18.8%AU$6.50AU$3.34AU$2.8412
Apr ’24AU$5.10
AU$4.54
-10.9%
15.5%AU$6.00AU$3.34AU$2.7412
Mar ’24AU$4.45
AU$4.45
+0.06%
12.9%AU$5.35AU$3.34AU$2.7612
Feb ’24AU$4.81
AU$4.47
-7.0%
14.3%AU$5.50AU$3.25AU$2.8911
Jan ’24AU$4.29
AU$4.32
+0.7%
16.4%AU$5.50AU$3.25AU$4.3911
Dec ’23AU$4.80
AU$4.32
-10.0%
16.4%AU$5.50AU$3.25AU$4.1111
Nov ’23AU$4.24
AU$4.25
+0.3%
17.6%AU$5.50AU$3.25AU$3.8511

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Doctor Care Anywhere Group

AU$23.8m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.064

7D

-5.9%

1Y

36.2%

Nova Eye Medical

AU$33.2m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.14

7D

-3.3%

1Y

11.5%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

7D

-12.5%

1Y

n/a